GRAL GRAIL, Inc. - Common Stock
关于 GRAIL, Inc. - Common Stock 公司概况（来自维基百科）
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
阅读更多
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Activities
Illumina's own research showed that repeatedly sequencing DNA in the bloodstream made it possible to detect floating bits of DNA from cancer cells more accurately. It initially aimed to recruit greater than 100,000 people into its clinical trials in order to accumulate the sizeable data required to detect and interpret cancer biomarkers.
Galleri test
As of November 2020 Galleri investigated three multi-cancer screening tests.
In June 2021 Galleri launched their liquid biopsy or multi-cancer early detection test (MCED), which Grail called the Galleri test. Grail promoted the test as a "groundbreaking and potentially life-saving advance", although the results of early trials were poor. A subsequent large-scale NHS England trial was described as overhyped and unethical. As of 2024, Grail was facing discontent and legal action from investors.
In June 2025, an article in the New Yorker discussed an interview of their medicine and science writer regarding the test and its recent history with a focus on its potential for adaptation as research continues in its product development through clinical investigations.
On 17 October 2025, BBC news carried positive coverage of test results just presented at the European Society for Medical Oncology. However, as of October 20, 2025 the results of the PATHFINDER 2 study have yet to be peer reviewed or published. Eric Topol reported a sensitivity of only 40% these false negatives failed to discover cancer that emerged during the 12-month follow-up.
Company history
Grail began as a San Francisco biotechnology and pharmaceutical startup company in 2015, the parent company being Illumina of San Diego, which produces most of the DNA sequencing machines that scientists use to study human biology and diagnose rare genetic diseases. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business. According to the San Francisco Business Times, he correctly predicted how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors. According to Forbes in 2017, 20% of Grail's profits are kept by Illumina.
In September 2020, Illumina announced an agreement to purchase Grail outright for $7.1 billion.
On November 27, 2020, Grail announced a commercial partnership with the National Health Service (England) (NHS), to trial the Galleri test, reporting in 2026.
In March 2021, the Federal Trade Commission (FTC) sued to block the vertical merger. In September 2022, an administrative judge ruled against the FTC's position on antitrust grounds.
In June 2023, Grail disclosed that letters were mailed to 408 patients incorrectly informing them that they may have cancer. The company blamed the incident on PWNHealth, saying that it was due to a software configuration issue, not due to incorrect Galleri test results.
In October 2023, the European Commission ordered Grail to be divested from Illumina within the next twelve months. The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $1 billion to fund 2.5 years of operations per the EC's divestment plan. The spinoff was completed in June 2024, with Grail trading on the Nasdaq with ticker symbol GRAL and Illumina retaining a 14.5% share of Grail.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
GRAL 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
GRAL 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
GRAL 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 4 26.7%
- 买入 5 33.3%
- 持有 6 40.0%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
8 位分析师 · 2026-08-19收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-2.56 | $-2.71 | 0.15% |
| 2026年3月31日 | $-2.29 | $-2.82 | 0.53% |
| 2025年12月31日 | $-2.44 | $-2.76 | 0.32% |
| 2025年9月30日 | $-2.46 | $-3.59 | 1.1% |
| 2025年6月30日 | $-3.18 | $-3.64 | 0.46% |
| 2025年3月31日 | $-3.10 | $-4.17 | 1.1% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| GRAL | $3.45B | -7.7 | 17.2% | -277.5% | -16.7% | — |
| VKTX | $4.04B | -11.0 | — | — | -47.3% | — |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | — |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| IOVA | $1.12B | -2.5 | 60.6% | -148.4% | -56.0% | — |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | — |
| IMNM | $2.43B | -8.8 | -23.2% | -3060.0% | -47.0% | — |
| CLDX | $1.81B | -7.0 | -78.0% | -16748.0% | -43.8% | — |
| IRON | $3.01B | -13.2 | — | — | -31.3% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 15
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $147M | $126M | $93M | |
| R&D Expense | $196M | $322M | $339M | |
| SG&A Expense | $159M | $214M | $200M | |
| Operating Expenses | $709M | $2.31B | $1.61B | |
| Operating Income | $-562M | $-2.19B | $-1.52B | |
| Interest Income | $29M | $27M | $8M | |
| Other Non-op | $-993.0K | $64.0K | $-208.0K | |
| Pretax Income | $-535M | $-2.16B | $-1.51B | |
| Income Tax | $-126M | $-135M | $-42M | |
| Net Income | $-408M | $-2.03B | $-1.47B | |
| EPS (Basic) | $-11.11 | $-63.54 | $-47.21 | |
| EPS (Diluted) | $-11.11 | $-63.54 | $-47.21 | |
| Shares (Basic) | 36,753,751 | 31,901,259 | 31,049,148 | |
| Shares (Diluted) | 36,753,751 | 31,901,259 | 31,049,148 | |
| EBITDA | $-562M | $-2.19B | · |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $250M | $214M | $97M | |
| Receivables | $18M | $20M | $17M | |
| Prepaid Expense | $15M | $17M | $20M | |
| Current Assets | $954M | $820M | $156M | |
| PP&E (Net) | $52M | $69M | $85M | |
| PP&E (Gross) | $122M | $123M | $121M | |
| Accum. Depreciation | $70M | $54M | $36M | |
| Goodwill | · | $0 | $889M | |
| Intangibles | $1.85B | $2.02B | $2.69B | |
| Other Non-current Assets | $7M | $8M | $8M | |
| Total Assets | $2.92B | $2.98B | $3.91B | |
| Accounts Payable | $2M | $5M | $20M | |
| Accrued Liabilities | $64M | $57M | $74M | |
| Current Liabilities | $80M | $77M | $164M | |
| Capital Leases | $43M | $55M | $70M | |
| Deferred Tax | $219M | $346M | $33M | |
| Other Non-current Liabilities | $3M | $2M | $1M | |
| Total Liabilities | $344M | $480M | $268M | |
| Common Stock | $40.0K | $34.0K | · | |
| Paid-in Capital | $12.79B | $12.31B | · | |
| Retained Earnings | $-10.21B | $-9.80B | $-7.78B | |
| AOCI | $3M | $1M | $1M | |
| Stockholders' Equity | $2.58B | $2.50B | · | |
| Liabilities + Equity | $2.92B | $2.98B | $3.91B | |
| Shares Outstanding | 40,331,360 | 33,893,409,000 | 0 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $58M | $86M | $97M | |
| Deferred Tax | $-126M | $-134M | $-38M | |
| Amort. of Intangibles | $134M | $134M | $134M | |
| Operating Cash Flow | $-299M | $-577M | $-596M | |
| CapEx | $909.0K | $5M | $13M | |
| Investing Cash Flow | $-85M | $-551M | $-13M | |
| Financing Cash Flow | $423M | $1.24B | $464M | |
| Net Change in Cash | $39M | $116M | $-145M | |
| Taxes Paid | $1M | · | · | |
| Free Cash Flow | $-300M | $-582M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Margin | -382.0% | -1743.0% | · | |
| Net Margin | -277.5% | -1613.9% | · | |
| Pretax Margin | -363.2% | -1721.7% | · | |
| EBITDA Margin | -382.0% | -1743.0% | · | |
| ROA | -13.8% | -58.8% | · | |
| ROE | -16.7% | -79.6% | · | |
| ROIC | -16.7% | -82.0% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 12.0 | 10.7 | · | |
| Quick Ratio | 3.4 | 3.0 | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.6 | 6.7 | · |
增长率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue YoY | 17.2% | 34.9% | 67.6% | |
| Revenue CAGR 3Y | 38.4% | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $147M | $126M | · | |
| Net Income TTM | $-408M | $-2.03B | · | |
| Market Cap | $3.45B | $605M | · | |
| P/E | -7.7 | -0.3 | · | |
| P/S | 23.5 | 4.8 | · | |
| P/B | 1.3 | 0.2 | · | |
| P / Tangible Book | 4.7 | 1.2 | · | |
| P / Cash Flow | -11.5 | -1.0 | · | |
| P / FCF | -11.5 | -1.0 | · | |
| Earnings Yield | -13.0% | -356.0% | · |
损益表 15
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $41M | $44M | $36M | $36M | $32M | $38M | $29M | $32M | $27M | $30M | $21M | |
| R&D Expense | $47M | $48M | $47M | $49M | $47M | $54M | $48M | $78M | $94M | $102M | · | · | |
| SG&A Expense | $51M | $43M | $39M | $37M | $38M | $45M | $42M | $47M | $67M | $57M | · | · | |
| Operating Expenses | $218M | $177M | $168M | $161M | $194M | $185M | $175M | $212M | $1.67B | $254M | $225M | $933M | |
| Operating Income | $-174M | $-136M | $-124M | $-125M | $-159M | $-154M | $-137M | $-184M | $-1.64B | $-227M | $-195M | $-912M | |
| Interest Income | $7M | $8M | $8M | $6M | $7M | $8M | $9M | $12M | $3M | $3M | $1M | $3M | |
| Other Non-op | $-155.0K | $256.0K | $-64.0K | $466.0K | $-811.0K | $-584.0K | $578.0K | $-561.0K | $5.0K | $42.0K | $213.0K | $-196.0K | |
| Pretax Income | $-167M | $-128M | $-117M | $-119M | $-153M | $-146M | $-127M | $-172M | $-1.64B | $-224M | $-193M | $-910M | |
| Income Tax | $-56M | $-34M | $-17M | $-30M | $-39M | $-40M | $-30M | $-47M | $-53M | $-6M | $-6M | $-19M | |
| Net Income | $-110M | $-93M | $-99M | $-89M | $-114M | $-106M | $-97M | $-126M | $-1.59B | $-219M | $-885M | $-891M | |
| EPS (Basic) | $-2.56 | $-2.29 | $-2.37 | $-2.46 | $-3.18 | $-3.10 | $-1.49 | $-3.94 | $-51.06 | $-7.05 | $-6.04 | $-28.71 | |
| EPS (Diluted) | $-2.56 | $-2.29 | $-2.37 | $-2.46 | $-3.18 | $-3.10 | $-1.49 | $-3.94 | $-51.06 | $-7.05 | $-6.04 | $-28.71 | |
| Shares (Basic) | 43,112,595 | 40,640,879 | -69,472,094 | 36,124,256 | 35,793,154 | 34,308,435 | -62,077,091 | 31,880,054 | 31,049,148 | 31,049,148 | 0 | 0 | |
| Shares (Diluted) | 43,112,595 | 40,640,879 | -69,472,094 | 36,124,256 | 35,793,154 | 34,308,435 | -62,077,091 | 31,880,054 | 31,049,148 | 31,049,148 | 0 | 0 | |
| EBITDA | $-174M | $-136M | · | $-125M | $-159M | $-154M | · | $-184M | $-1.64B | · | · | · |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $56M | $69M | $250M | $127M | $127M | $134M | $214M | $854M | $959M | · | $97M | · | |
| Receivables | $20M | $20M | $18M | $16M | $16M | $19M | $20M | · | · | · | · | · | |
| Prepaid Expense | $16M | $17M | $15M | $15M | $13M | $15M | $17M | $20M | $21M | · | · | · | |
| Current Assets | $915M | $877M | $954M | $589M | $652M | $728M | $820M | $910M | $1.02B | · | · | · | |
| PP&E (Net) | $44M | $48M | $52M | $56M | $60M | $65M | $69M | · | · | · | · | · | |
| PP&E (Gross) | · | · | $122M | · | · | · | $123M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $70M | · | · | · | $54M | · | · | · | · | · | |
| Goodwill | · | · | · | · | · | · | $0 | $0 | $0 | · | $889M | · | |
| Intangibles | $1.78B | $1.82B | $1.85B | $1.89B | $1.92B | $1.98B | $2.02B | $2.05B | $2.09B | · | · | · | |
| Other Non-current Assets | $7M | $7M | $7M | $7M | $7M | $7M | $8M | $8M | $8M | · | · | · | |
| Total Assets | $2.84B | $2.80B | $2.92B | $2.60B | $2.70B | $2.85B | $2.98B | $3.12B | $3.27B | · | · | · | |
| Accounts Payable | $7M | $5M | $2M | $3M | $6M | $6M | $5M | · | · | · | · | · | |
| Accrued Liabilities | $64M | $58M | $64M | $58M | $49M | $54M | $57M | $69M | $57M | · | · | · | |
| Current Liabilities | $84M | $75M | $80M | $77M | $71M | $75M | $77M | $94M | $88M | · | · | · | |
| Capital Leases | $81M | $41M | $43M | $45M | $48M | $51M | $55M | $59M | $62M | · | · | · | |
| Deferred Tax | $134M | $184M | $219M | $236M | $266M | $305M | $346M | $375M | $422M | · | · | · | |
| Other Non-current Liabilities | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | · | · | · | |
| Total Liabilities | $301M | $303M | $344M | $361M | $388M | $434M | $480M | $530M | $575M | · | · | · | |
| Common Stock | $45.0K | $41.0K | $40.0K | $36.0K | $36.0K | $35.0K | $34.0K | $33.0K | $31.0K | · | · | · | |
| Paid-in Capital | $12.96B | $12.80B | $12.79B | $12.35B | $12.34B | $12.32B | $12.31B | $12.29B | $12.27B | · | · | · | |
| Retained Earnings | $-10.42B | $-10.30B | $-10.21B | $-10.11B | $-10.02B | $-9.91B | $-9.80B | $-9.71B | $-9.58B | · | · | · | |
| AOCI | $2M | $2M | $3M | $2M | $2M | $2M | $1M | $2M | $1M | · | · | · | |
| Stockholders' Equity | $2.54B | $2.50B | $2.58B | $2.24B | $2.31B | $2.41B | $2.50B | $2.59B | $2.70B | · | · | · | |
| Liabilities + Equity | $2.84B | $2.80B | $2.92B | $2.60B | $2.70B | $2.85B | $2.98B | $3.12B | $3.27B | · | · | · | |
| Shares Outstanding | 44,666,234 | 41,134,219 | 40,331,360 | 36,160,998 | 36,047,799 | 35,296,858 | 33,893,409 | 33,203,744 | 31,049,148 | · | 0 | · |
现金流 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $20M | $17M | $14M | $14M | $14M | $16M | $14M | $17M | $26M | $29M | $25M | $25M | |
| Deferred Tax | $-57M | $-35M | $-17M | $-30M | $-39M | $-40M | $-29M | $-47M | $-53M | $-5M | $-4M | $-18M | |
| Amort. of Intangibles | $33M | $33M | $30M | $35M | $33M | $33M | $30M | $35M | $35M | $35M | $30M | $35M | |
| Restructuring | · | · | · | · | · | · | · | $19M | · | · | · | · | |
| Operating Cash Flow | $-81M | $-87M | $-64M | $-63M | $-77M | $-95M | $-93M | $-105M | $-172M | $-207M | $-129M | $-158M | |
| CapEx | $432.0K | $503.0K | $94.0K | $384.0K | $369.0K | $62.0K | $303.0K | $971.0K | $1M | $3M | · | · | |
| Investing Cash Flow | $-47M | $-93M | $-237M | $67M | $70M | $15M | $-546M | $-971.0K | $-1M | $-3M | $-4M | $-3M | |
| Financing Cash Flow | · | · | $423M | $0 | $0 | $0 | $0 | $0 | $932M | $312M | $86M | $74M | |
| Net Change in Cash | $-14M | $-180M | $123M | $3M | $-6M | $-80M | $-640M | $-105M | $759M | $102M | $-47M | $-87M | |
| Free Cash Flow | · | $-87M | · | · | · | $-95M | · | · | · | · | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -388.9% | -332.9% | · | -346.2% | -446.9% | -482.5% | · | -640.5% | -5133.9% | · | · | · | |
| Net Margin | -246.7% | -228.5% | · | -245.8% | -320.7% | -333.6% | · | -438.7% | -4958.8% | · | · | · | |
| Pretax Margin | -373.1% | -312.7% | · | -328.0% | -430.1% | -459.9% | · | -601.7% | -5125.1% | · | · | · | |
| EBITDA Margin | -388.9% | -332.9% | · | -346.2% | -446.9% | -482.5% | · | -640.5% | -5133.9% | · | · | · | |
| ROA | -4.0% | -3.3% | · | -3.1% | -3.8% | -7.5% | · | -8.1% | -97.0% | · | · | · | |
| ROE | -4.5% | -3.8% | · | -3.7% | -4.5% | -8.8% | · | -9.7% | -117.6% | · | · | · | |
| ROIC | -4.5% | -4.0% | · | -4.2% | -5.1% | -4.6% | · | -5.2% | -58.9% | · | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 11.7 | · | 7.6 | 9.2 | 9.7 | · | 9.7 | 11.6 | · | · | · | |
| Quick Ratio | 0.9 | 1.2 | · | 1.8 | 2.0 | 2.0 | · | 9.1 | 10.9 | · | · | · |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 2.5 | 2.1 | · | 4.4 | 4.4 | 3.3 | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $157M | $144M | · | $132M | $128M | $119M | · | $108M | $102M | · | · | · | |
| Net Income TTM | $-406M | $-402M | · | $-435M | $-1.93B | $-2.04B | · | $-2.82B | $-2.89B | · | · | · | |
| Market Cap | $3.05B | $2.13B | · | $2.14B | $1.85B | $901M | · | $457M | $477M | · | · | · | |
| P/E | -6.5 | -4.7 | · | -4.7 | -0.8 | -0.4 | · | -0.2 | -0.2 | · | · | · | |
| P/S | 19.4 | 14.7 | · | 16.2 | 14.5 | 7.6 | · | 4.2 | 4.7 | · | · | · | |
| P/B | 1.2 | 0.9 | · | 1.0 | 0.8 | 0.4 | · | 0.2 | 0.2 | · | · | · | |
| P / Tangible Book | 4.0 | 3.1 | · | 6.0 | 4.7 | 2.1 | · | 0.9 | 0.8 | · | · | · | |
| P / Cash Flow | · | -24.4 | · | · | · | -9.5 | · | · | · | · | · | · | |
| P / FCF | · | -24.3 | · | · | · | -9.5 | · | · | · | · | · | · | |
| Earnings Yield | -15.4% | -21.3% | · | -21.4% | -119.2% | -255.1% | · | -659.6% | -605.3% | · | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | |
|---|---|---|---|---|
| 收入 | $147M | $126M | $93M | $56M |
| 营业利润率 % | -382.0% | -1743.0% | — | — |
| 净收入 | $-408M | $-2.03B | $-1.47B | $-5.40B |
| 稀释后每股收益 (EPS) | $-11.11 | $-63.54 | $-47.21 | $-173.89 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | |
|---|---|---|---|---|
| 流动比率 | 12.0 | 10.7 | — | — |
| 速动比率 | 3.4 | 3.0 | — | — |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | |
|---|---|---|---|---|
| 自由现金流 | $-300M | $-582M | — | — |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 413 家申报者 · $2.2B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 67 (+16 与上一季度对比) | 45 (-49 与上一季度对比) | 106 (+8 与上一季度对比) | 102 (-12 与上一季度对比) | +6.7M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 8 位内幕人士 · 2 位高管 · 5 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Joshua J. Ofman | Chief Executive Officer | 2026年6月1日 A | 402271 | 0 | 0 | $0 |
| Andrew John Partridge | Chief Growth Officer | 2026年6月4日 S | 163738 | 0 | 1 | $-91070 |
| William J Chase | 董事 | 2026年7月15日 A | 42978 | 0 | 0 | $0 |
| Steven Mizell | 董事 | 2026年7月15日 A | 42830 | 0 | 0 | $0 |
| Gregory L Summe | 董事 | 2026年7月15日 A | 45672 | 0 | 0 | $0 |
| Sarah Krevans | 董事 | 2026年6月18日 A | 42628 | 0 | 0 | $0 |
| ILLUMINA, INC. | 10% 所有者 | 2025年11月17日 S | 3502126 | 0 | 1 | $-79850000 |
| Chun R Ding | 10% 所有者 | 2024年10月9日 P | 3644855 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 50 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.90% | 18597 NS | 2026年4月30日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.63% | 59651 NS | 2026年4月30日 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.21% | 87481 SH | 2026年8月8日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.20% | 2336 SH | 2026年8月8日 | 每日 |
| IBB · iShares Trust | 0.19% | 291644 SH | 2026年8月8日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.18% | 36116 SH | 2026年8月8日 | 每日 |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.17% | 67501 NS | 2026年5月31日 | N-PORT |
| IWN · iShares Trust | 0.17% | 385837 SH | 2026年8月8日 | 每日 |
| ESSC · Strategy Shares | 0.15% | 712 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.14% | 1439 NS | 2026年5月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.09% | 237749 SH | 2026年8月8日 | 每日 |
| IWM · iShares Trust | 0.08% | 1053632 SH | 2026年8月8日 | 每日 |
| GSSC · Goldman Sachs ETF Trust | 0.08% | 11051 NS | 2026年5月31日 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.08% | 1185 NS | 2026年4月30日 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.07% | 9665 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.06% | 1654 NS | 2026年5月31日 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.06% | 2459 SH | 2026年8月8日 | 每日 |
| RSSL · Global X Funds | 0.06% | 15208 NS | 2026年4月30日 | N-PORT |
| ESML · iShares Trust | 0.05% | 22118 SH | 2026年8月8日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.05% | 117357 NS | 2026年4月30日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.05% | 143168 NS | 2026年5月31日 | N-PORT |
| ISCG · iShares Trust | 0.04% | 6428 SH | 2026年8月8日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.04% | 114187 SH | 2026年8月8日 | 每日 |
| UWM · ProShares Trust | 0.04% | 1294 NS | 2026年5月31日 | N-PORT |
| ISCB · iShares Trust | 0.04% | 1688 SH | 2026年8月8日 | 每日 |
| ISCV · iShares Trust | 0.04% | 3927 SH | 2026年8月8日 | 每日 |
| SMLF · iShares Trust | 0.03% | 20757 SH | 2026年8月8日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 16096 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 374291 SH | 2026年8月8日 | 每日 |
| URTY · ProShares Trust | 0.03% | 1307 NS | 2026年5月31日 | N-PORT |
| WSML · iShares Trust | 0.02% | 2078 SH | 2026年8月8日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.02% | 1178 NS | 2026年4月30日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 1399 NS | 2026年5月31日 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.01% | 23351 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.01% | 33 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 4910 NS | 2026年4月30日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 11015 NS | 2026年5月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.01% | 51657 NS | 2026年4月30日 | N-PORT |
| IWV · iShares Trust | 0.00% | 11704 SH | 2026年8月8日 | 每日 |
| IETC · iShares U.S. ETF Trust | 0.00% | 375 SH | 2026年8月8日 | 每日 |
| ACVF · ETF Opportunities Trust | 0.00% | 82 NS | 2026年4月30日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 45817 SH | 2026年8月8日 | 每日 |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 192 NS | 2026年5月31日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 17955 NS | 2026年5月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 9362 NS | 2026年4月30日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 4660 NS | 2026年4月30日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.00% | 3550 NS | 2026年4月30日 | N-PORT |
| DFLV · Dimensional ETF Trust | 0.00% | 321 NS | 2026年4月30日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1228926 SH | 2026年8月8日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3407 SH | 2026年8月8日 | 每日 |